The present invention relates to methods of treating a tumor or treating cancer in a subject having a p53 DNA contact mutation that involve administering, to the subject, a ROCK inhibitor. Also disclosed is a method of identifying a subject as a candidate for such treatment.

The present invention relates to a type 1 interferon neutralizing FC-fusion protein and a use thereof and, more specifically, to: a dimer-type polypeptide to which a monomer comprising an interferon receptor fragment or an antibody Fc fragment is bound; a preparation method there for; and a pharmaceutical composition comprising same. The type 1 interferon neutralizing FC-fusion protein of the present invention blocks binding between type 1 interferon and an interferon receptor, and has an excellent ability of inhibiting the signaling and biological activities of interferon, thereby enabling diseases mediated by a type 1 interferon to be effectively treated.

Disclosed are peptides comprising a p53 peptide and a BH3-only protein. In some aspects, wherein the BH3-only protein is BAD, BID, BIM, NOXA. Disclosed are nucleic acid sequences comprising a sequence capable of encoding a p53 peptide operably linked to a nucleic acid sequence capable of encoding a BH3-only protein. Disclosed are nucleic acid sequences comprising a sequence capable of encoding one or more of the peptides disclosed herein. Disclosed are vectors comprising a nucleic acid sequence, wherein the nucleic acid sequence is capable of encoding one or more of the peptides disclosed herein. Also disclosed are methods of using the disclosed peptides, nucleic acid sequences, and vectors.

The present disclosure is directed to methods and compositions for inhibiting a cancer cell using nucleic acid sequences encoding elephant p53 or elephant p53 amino acid sequences.

Provided are methods of generating chimeric antigen receptors (CAR). In some embodiments, library screening of CAR is performed by generating a vector encoding the CAR from random attachment of vectors from libraries of vectors encoding antigen-binding domains (e.g., scFv regions), hinge regions, and endodomains. In some embodiments, the vectors contain a transposon.

The present invention is based, in part, on the identification of TP53 dependency biomarkers, including MDM2, MDM4, USP7, and Wip1/PPM1D, as well as modulators and methods of use thereof, for identifying, assessing, preventing, and treating Ewing sarcoma.

A composition according to an embodiment of the present disclosure includes porous artificial chaperone particles having an average pore diameter of 1 to 100 nm, thereby stapling an alpha helical polypeptide to immobilize a random coiled tertiary-structure of the polypeptide into a stable alpha-helix structure, and significantly improving stability and efficiency of the polypeptide.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

An agent which promotes homology directed DNA repair for use in haematopoietic stem and/or progenitor cell gene therapy, wherein said haematopoietic stem cells are gene edited. Use of an agent which promotes homology directed DNA repair, for increasing the survival and/or engraftment of gene edited haematopoietic stemand/or progenitorcells or for increasing the efficiency of gene editing of haematopoietic stem and/or progenitor cells.

This invention relates to materials, such as peptides, and methods to inhibit the aggregation transcription factors, for example p53 inhibitors, p63 inhibitors and p73 inhibitors. More specifically, the invention relates to cancer chemotherapeutics. More specifically, the invention provides pharmaceutical compositions and methods of treating cancer with certain peptides.